The amyloid-beta pathway in Alzheimer's disease: a plain language summaryopen access
- Authors
- Hampel, Harald; Hu, Yan; Hardy, John; Blennow, Kaj; Chen, Christopher; Perry, George; Kim, Seung Hyun; Villemagne, Victor L.; Aisen, Paul; Vendruscolo, Michele; Iwatsubo, Takeshi; Masters, Colin L.; Cho, Min; Lannfelt, Lars; Cummings, Jeffrey L.; Vergallo, Andrea
- Issue Date
- Jun-2023
- Publisher
- FUTURE MEDICINE LTD
- Keywords
- Alzheimer' s disease; amyloid beta; A beta plaques; biomarkers; dementia; protofibrils; tau
- Citation
- NEURODEGENERATIVE DISEASE MANAGEMENT, v.13, no.3, pp.141 - 149
- Indexed
- SCOPUS
- Journal Title
- NEURODEGENERATIVE DISEASE MANAGEMENT
- Volume
- 13
- Number
- 3
- Start Page
- 141
- End Page
- 149
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/188366
- DOI
- 10.2217/nmt-2022-0037
- ISSN
- 1758-2024
- Abstract
- What is this summary about?
This plain language summary of an article published in Molecular Psychiatry, reviews the evidence supporting the role of the amyloid-b (Ab) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the A beta pathway in the early stages of the disease.
Why is this important?
A beta is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of A beta plaques is a hallmark of AD. However, smaller, soluble aggregates of A beta - including Ab protofibrils - also play a role in the disease. Because A beta-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the A beta protein and its role in AD, summarizing the evidence showing that altered A beta clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD.
What are the key takeaways?
The physiological balance of brain A beta levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that A beta has a central role in driving AD progression. A better understanding of the A beta pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 신경과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.